Abstract
In the past, elective orthopedic surgery in hemophilic patients with inhibitors was usually not contemplated because of the high risk of bleeding complications. Thanks to the progress made in the development of bypassing therapies, elective surgery has become feasible; however, only centers that are already experienced can tackle this challenge. A strict collaboration amongst surgeons, hematologists, and physiotherapists is essential for a successful long-term outcome.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypassing activity. J Thromb Haemost 2:1700–1708
Abshire T, Kenet G (2004) Recombinant factor VIIa: review of afficacy, dosing regimens and safety in patients with congenital and acquired factor VIII and IX inhibitors. J Thromb Haemost 2:899–909
Ehrlich HJ, Henzl MJ, Gomperts ED (2002) Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 8:83–90
White GC II, Rosendaal F, Aledort LM et al (2001) Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 85:560
Gringeri A, Mannucci PM (2005) Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 11:611–619
Hay CR, Baglin TP, Collins PW et al (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 111:78–90
Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P and the Members of the French FEIBA Study Group (1997) Multicenter retrospective study on the utilisation of Feiba in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 77:1113–1119
Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR (2004) Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 10:174–178
Shapiro AD, Gilchrist GS, Hoots WK et al (1998) Prospective randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80:773–778
Santagostino E, Morfini M, Rocino A et al (2001) Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 86:954–958
Smith MP, Ludlam CA, Collins PW et al (2001) Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 86:949–953
Ludlam CA, Smith MP, Morfini M et al (2003) A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 120:808–813
Hoffman M, Monroe DM 3rd, Roberts HR (1998) Activated factor VII activates factor IX and X on the surface of activated platelets: thoughts on the mechanism of action of highdose activated factor VII. Blood Coagul Fibrinolysis 9(Suppl 1):S61–65
Butenas S, Brummel KE, Bouchard BA, Mann KG (2003) How factor VIIa works in hemophilia. J Thromb Haemost 1:1158–1160
Nilsson IM, Jonsson S, Sundqvist SB et al (1981) A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 58:38–44
Kroner BL (1999) Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 77(Suppl 1):33–37
Rodríguez-Merchán EC, Rocino A, Ewenstein B et al (2004) Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 10(Suppl 2):50–52
Solimeno LP, Perfetto OS, Pasta G, Santagostino E (2006) Total joint replacement in patients with inhibitors. Haemophilia 12(Suppl 3):113–116
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this chapter
Cite this chapter
Santagostino, E., Mancuso, M.E. (2008). Peri-operative and Post-operative Management of Hemophiliac Patients with Inhibitors. In: Caviglia, H.A., Solimeno, L.P. (eds) Orthopedic Surgery in Patients with Hemophilia. Springer, Milano. https://doi.org/10.1007/978-88-470-0854-0_7
Download citation
DOI: https://doi.org/10.1007/978-88-470-0854-0_7
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0853-3
Online ISBN: 978-88-470-0854-0
eBook Packages: MedicineMedicine (R0)